28 results about "Hepcidin" patented technology

The disclosure provides compositions and methods for the treatment and / or prevention of sickle cell disease.

Methods of increasing systemic iron availability in a human subject using plant-derived ferritin-bound iron are provided. In certain embodiments, ferritin-bound iron is orally administered in an amount effective to produce sustained systemic iron exposure characterized by measurable serum iron levels at least 24 hours after administration. In some embodiments, administration produces a delayed peak serum iron concentration and provides controlled systemic iron delivery relative to conventional iron supplements. In certain embodiments, administration of ferritin-bound iron results in a reduced hepcidin response relative to ferrous sulfate, thereby facilitating improved iron utilization. The ferritin-bound iron may be absorbed through receptor-mediated uptake mechanisms that provide controlled intracellular iron release and sustained systemic availability. The methods are useful for increasing systemic iron availability and for treating or preventing iron deficiency and iron deficiency anemia in human subjects.

The invention provides micropterus salmoides Hepcidin-1 (Ms-Hepcidin-1) and an application of a synthetic polypeptide of the micropterus salmoides Hepcidin-1 in preparation of an anti-fish virus drug. The research finds that the Ms-Hepcidin-1 synthetic polypeptide has a remarkable antiviral effect and is a novel antibacterial peptide with a function of inhibiting fish viruses. The Ms-Hepcidin-1 synthetic polypeptide and the recombinant eukaryotic expression vector of the Ms-Hepcidin-1 synthetic polypeptide can obviously reduce the transcription level of MCP, MMP and DNMT genes and the MCP protein level of LMBV, inhibit the replication of the LMBV and reduce the virus titer, and have an obvious fish virus resisting effect. Moreover, the polypeptide synthesized by Ms-Hepcidin-1 is simple to prepare, low in cost, safe to use and convenient to preserve, can be used as a novel antiviral functional gene product to prepare antiviral drugs for fishes, and has important significance on prevention and control of fish iridovirus diseases.

The present invention relates to daprodustat or a pharmaceutically acceptable salt thereof for use in reducing fatigue in a specific population of non-dialysis subjects with anemia associated with chronic kidney disease, characterized by baseline hepcidin and hsCRP levels.

Aspects of the present disclosure provide anti-TMPRSS6 antibodies and methods of using the same to promote hepcidin expression and treat iron overload related disorders such as hemopigmentation, sickle cell disease, thalassemia, hemolysis, Diamond-Blackfan anemia, myelodysplastic syndrome (MDS), and blood transfusion.

The application discloses an application of a TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, relates to the technical field of biology and medicine, and discloses an application of the TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, wherein the TLR4 / NF-kappa B signal path inhibitor is Danggui Buxue Decoction; the Danggui Buxue Decoction is composed of Astragalus and Angelica with a mass ratio of 5:1; the TLR4 / NF-kappa B signal path inhibitor is used for down-regulating expression of TLR4 protein and NF-kappa B protein in liver tissue; the improvement of hematopoietic function of anemic inflammatory includes increasing peripheral blood red blood cell count, white blood cell count, platelet count and hemoglobin level; the Danggui Buxue Decoction is used as the TLR4 / NF-kappa B inhibitor to improve anemic inflammatory, can down-regulate TLR4 / NF-kappa B expression, improve blood cells and hemoglobin, improve bone marrow pathology, reduce inflammatory factors and hepcidin, increase iron content, and provide a corresponding curative effect evaluation method, and provides a new choice for anemic inflammatory treatment.

This invention provides the application of Hepcidin-1 (Ms-Hepcidin-1) and its synthetic polypeptide in the preparation of antiviral drugs for largemouth bass. The invention reveals that the Ms-Hepcidin-1 synthetic polypeptide exhibits significant antiviral activity and is a novel antimicrobial peptide with the function of inhibiting fish viruses. Both the Ms-Hepcidin-1 synthetic polypeptide and its recombinant eukaryotic expression vector can significantly reduce the transcriptional levels of MCP, MMP, and DNMT genes and the MCP protein level of LMBV, inhibit LMBV replication, and reduce viral titers, demonstrating significant antiviral activity against fish viruses. Furthermore, the polypeptide synthesized from Ms-Hepcidin-1 is simple to prepare, low in cost, safe to use, and easy to store. As a novel antiviral functional gene product, it can be applied to the preparation of antiviral drugs for fish, which is of great significance for the prevention and control of iridovirus disease in fish.

To provide hepcidin analogs with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.SOLUTION: The present invention relates generally to hepcidin analog peptides and methods of making and using the same. In certain embodiments, hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention is directed to hepcidin peptide analogs comprising one or more peptide subunits, wherein the peptide subunits form a cyclized structure via an intramolecular bond, e.g., an intramolecular disulfide bond. In certain embodiments, cyclized structures have increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life compared to hepcidin or conventional hepcidin analogs when delivered orally.SELECTED DRAWING: None

The invention features methods of treating iron overload in a subject by administering BMP or hepcidin inhibitors, such as ALK2 inhibitors. The invention also features methods of decreasing iron levels in a subject by administering BMP or hepcidin inhibitors.

The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and / or prevention of a variety of diseases, conditions or disorders, including treatment and / or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

The application discloses application of a Hepcidin modulator. Abnormal increase of Hepcidin in a ventral hippocampus region in a senescence process drives imbalance of iron homeostasis of neurons, and further induces an anxiety-like phenotype. Pharmacodynamic verification shows that administration of a Hepcidin inhibitor to cells of the ventral hippocampus can effectively reverse anxiety behavior of a senescence model animal. The pharmaceutical composition described in the application takes the Hepcidin pathway as an intervention target, and an active ingredient thereof is selected from the following: (1) a high-affinity Hepcidin inhibitor NOX-H94; and (2) a recombinant adeno-associated virus vector carrying a Hepcidin-targeted interference sequence, which is used for silencing expression of Hepcidin in neurons of the ventral hippocampus in vivo. The above-mentioned preparation provides a new molecular target and a drug candidate for clinical intervention of senescence-related emotional disorders.

The application relates to a hepcidin chemiluminescence immunoassay kit and a non-diagnostic method for detecting hepcidin, the kit comprising a calibrator, a quality control, an integrated bifunctional antibody reagent, a magnetic particle reagent, a cleaning solution and a chemiluminescence substrate solution; the integrated bifunctional antibody reagent is a buffer containing HEP-specific antibodies covalently connected with fluorescein isothiocyanate and alkaline phosphatase through pH-sensitive connecting bonds; the magnetic particle reagent is a magnetic microsphere suspension coated with a goat anti-fluorescein isothiocyanate antibody; the cleaning solution is a buffer containing a surfactant composition, and the surfactant composition comprises nonionic surfactants, zwitterionic surfactants and high-molecular nonionic surfactants. The hepcidin chemiluminescence immunoassay kit has the effects of ultra-low background noise, ultra-high sensitivity, ultra-wide linear range and simplified operation of end users by means of the integrated bifunctional antibody reagent and the surfactant composition cleaning solution.

The present invention provides peptides, which are hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.

Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and / or conditions associated with hepcidin deficiency or suppression.

This invention provides a method for treating anemia in subjects with myelofibrosis. [Solution] A method is provided for treating anemia in a subject with myelofibrosis, comprising administering an effective amount of a hemoduvelin-induced BMP signaling antagonist, a hepcidin antagonist, to the subject.

Aspects of the application provide siRNAs that target and reduce the expression of hemochromatosis type 2 (HFE2), compositions and methods of using the same to reduce serum hepcidin concentration and treat anemias of inflammation, iron-restricted anemias and / or conditions associated with anemia.

The present invention belongs to the technical field of medicine. Disclosed in the present invention is a new pharmaceutical use of hepcidin, specifically the use of hepcidin in the preparation of a drug for blocking ferroptosis of a collecting tubule in acute kidney injuries and protecting kidney function. It has been demonstrated in the present invention that both renal endogenous and exogenous hepcidin can alleviate tubular injury and improve renal function in ischemia-reperfusion-induced acute kidney injury by inhibiting ferroptosis in intercalated cells of the collecting tubule. Disclosed in the present invention is a drug for alleviating ferroptosis of a collecting tubule and protecting kidney function in ischemic-reperfusion-induced acute kidney injury. The drug is an intraperitoneal injection prepared by dissolving hepcidin at a therapeutic concentration in PBS.

The disclosure provides compositions and methods for the treatment and / or prevention of sickle cell disease.

The present disclosure provides small molecule compounds that are hepcidin mimetics. In addition, the present disclosure also encompasses pharmaceutical compositions that include the small molecule compounds and a pharmaceutically acceptable carrier, excipient or vehicle. The present disclosure also encompasses kits that include the small molecule compounds or the pharmaceutical compositions. The present disclosure also encompasses methods of using the hepcidin mimetic compounds.

In the present invention, we identified the hepatokine FGL1 as a previously unreported hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent suppressor of hepcidin in vitro and in vivo. Deficiency of Fgl1 in mice (Fgl1- / -) results in lower hepcidin repression after hemorrhage. Finally, we clearly demonstrated that FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the canonical BMP-SMAD signaling cascade that controls hepcidin regulation. Therefore, the present invention relates to methods for preventing or treating iron overload-related diseases by targeting the hepatokine FGL1, a novel hepcidin repressor.

Aspects of the application provide hepcidin antagonists and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Anemia, defined as a reduction in the amount of functional red blood cells in circulation, is a major cause of disease affecting one-third of the world's population. Iron is essential for hemoglobin, the functional component of red blood cells, to store and transport oxygen. Hepcidin, a liver-derived peptide, is a key regulator of iron homeostasis. During anemia, the erythropoietic hormone erythroferon regulates hepcidin synthesis to ensure an adequate supply of iron to the bone marrow for red blood cell synthesis. However, accumulating evidence suggests that other factors may perform a similar function. We identified the hepatokine FGL1 as a previously undescribed hepcidin suppressor that is highly induced in the liver in response to hypoxia during recovery from anemia and in thalassemia mice. We demonstrated that FGL1 is a potent hepcidin suppressor in vitro and in vivo. Deletion of Fgl1 in mice blunts hepcidin suppression after hemorrhage.Finally, FGL1 is a BMP antagonist that directly binds to BMP6 and impairs the BMP-SMAD signaling cascade that controls hepcidin regulation.Therefore, the present invention relates to an FGL1 polypeptide for use in treating patients suffering from iron deficiency-related diseases.

To provide a method for treating and / or preventing polycythemia vera (PV).SOLUTION: A method includes administering a hepcidin analog made of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof to a subject. In the formula (I) R1-X-Y-R2, each of X and Y represents a specific peptide sequence, a peptide of the formula (I) is optionally pegylated in R1, X or Y, a side chain of amino acid of the peptide is optionally conjugated with a lipophilic substituent or a polymer part.SELECTED DRAWING: Figure 1

The invention discloses a fish-derived antibacterial peptide as well as a preparation method and application thereof, the antibacterial peptide is derived from fish-derived Piscid-1 and Hepcidin, and the antibacterial peptide sequentially comprises a signal peptide, an antibacterial peptide, tag protein and other functional elements from an N end to a C end. According to the invention, by optimizing the connection method and sequence of fish-derived Piscid-1, Hepcidin, signal peptide, tag protein and other functional elements in the fish-derived antibacterial peptide, a plurality of engineering bacteria for expressing monomer fish-derived antibacterial peptide and tandem fish-derived antibacterial peptide are obtained, and optimal biological activity and function synergy are realized. The fish-derived antibacterial peptide and the engineering bacteria thereof can be used as feed additives to be applied to fish culture, and can play roles in promoting growth, enhancing immune performance, improving intestinal flora and the like. The method has a wide application prospect.

This application discloses a functional composition, a conditioning agent, and its application in the preparation of a supplement for improving sub-health conditions. The functional composition comprises a first active ingredient and a second active ingredient. The first active ingredient includes red raspberry and carrot, and the second active ingredient includes one or more of artichoke extract and Fusarium oxysporin. The mass ratio of the first active ingredient to the second active ingredient is (1-10000):(1-10000). This application, through the formulation of active ingredients, promotes the body's absorption of iron through mechanisms such as intestinal iron absorption and / or regulation of hepcidin, thereby supplementing iron and significantly improving iron deficiency. Therefore, the functional composition provided by this application can be used to improve symptoms such as anemia caused by functional iron deficiency. Simultaneously, the functional composition also has beneficial effects such as regulating constitution, replenishing qi and blood, and improving sub-health conditions.

The present invention relates to a Matriptase-2 (MT2) inhibitor, a TMPRSS6 inhibitor, an iron transporter blocking agent, or a hepcidin enhancer. In particular, the present invention relates to the use of compounds capable of reducing at least one of systemic iron levels, transferrin saturation (Tsat), non-transferrin binding iron (NTBI), and labile plasma iron (LPI). This can be accomplished by inhibiting the expression of a target gene, wherein the target gene can be transmembrane protease serine 6 (TMPRSS6). Further, the invention relates to compositions comprising said compounds and to methods of using such compounds and / or compositions. Uses may include therapeutic uses, such as for reducing iron overload and preventing iron-related toxicity before, during or after chemotherapy pretreatment, stem cell transplantation and colonization.